Login to Your Account

Clinic Roundup

Thursday, February 24, 2011
Theratechnologies Inc., of Montreal, announced a new clinical program for muscle wasting in chronic obstructive pulmonary disease (COPD) using the company's lead compound, tesamorelin, a human growth hormone releasing factor analogue. The company said it will develop tesamorelin in muscle wasting in patients with COPD as its second indication.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription